AI-generated analysis. Always verify with the original filing.
FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based therapies for chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company is conducting a best-efforts public offering of up to 1,136,363 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) and accompanying Warrants, with an assumed combined public offering price of $4.40 per share and accompanying Warrant, aiming to raise approximately $4.3 million in net proceeds. The offering is being conducted to fund working capital and general corporate purposes, as the company currently has no revenue and is in the development stage. FibroBiologics is listed on the Nasdaq Capital Market under the ticker 'FBLG' but faces delisting risks due to non-compliance with Nasdaq's Bid-Price Rule and Market Value of Publicly Held Shares Rule, prompting a 1-for-20 reverse stock split effective March 30, 2026, to regain compliance.
Offering Amount
$10.4M
Shares Offered
310,000,000
Price Range
$18.00 – $20.00
Shares Offered
1,136,363
Offering Amount
$5.0 million
Share Type
Common Stock
Exchange
NASDAQ Capital Market
Ticker
FBLG
Use of Proceeds: Working capital and general corporate purposes.
Clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs.